AnaptysBio (NASDAQ:ANAB) Issues Quarterly Earnings Results

AnaptysBio (NASDAQ:ANAB) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58, Zacks reports. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million.

AnaptysBio Stock Performance

ANAB stock traded up $1.84 on Wednesday, reaching $21.72. The company had a trading volume of 185,546 shares, compared to its average volume of 344,814. The company’s fifty day moving average is $33.59 and its 200 day moving average is $29.94. The company has a market cap of $595.87 million, a P/E ratio of -3.56 and a beta of -0.24. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $41.31.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. UBS Group lifted their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Truist Financial upped their price target on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a research note on Thursday, October 31st. Guggenheim lifted their price objective on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, JPMorgan Chase & Co. raised their price target on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and a consensus target price of $55.73.

Insider Transactions at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the transaction, the insider now directly owns 15,398 shares in the company, valued at approximately $595,440.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other AnaptysBio news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were purchased at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the purchase, the insider now owns 7,794,996 shares in the company, valued at approximately $284,517,354. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares of the company’s stock, valued at $595,440.66. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,440 shares of company stock valued at $892,936 over the last three months. 33.70% of the stock is currently owned by insiders.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.